These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 21391734)
1. Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics. Slobodova Z; Ehrmann J; Krejci V; Zapletalova J; Melichar B Neoplasma; 2011; 58(3):189-97. PubMed ID: 21391734 [TBL] [Abstract][Full Text] [Related]
2. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347 [TBL] [Abstract][Full Text] [Related]
3. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients. Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919 [TBL] [Abstract][Full Text] [Related]
4. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434 [TBL] [Abstract][Full Text] [Related]
5. Frequency Of Hormone Receptors And Her-2/Neu Receptor Positivity In Different Histology In Breast Cancer Patients. Ravi R; Haider G; Ahmed K; Zahoor S; Sami A; Lata R J Ayub Med Coll Abbottabad; 2020; 32(3):323-326. PubMed ID: 32829544 [TBL] [Abstract][Full Text] [Related]
6. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737 [TBL] [Abstract][Full Text] [Related]
7. Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status. Wilder RB; Curcio LD; Khanijou RK; Eisner ME; Kakkis JL; Chittenden L; Agustin J; Lizarde J; Mesa AV; Macedo JC; Ravera J; Tokita KM Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):799-803. PubMed ID: 20869583 [TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046 [TBL] [Abstract][Full Text] [Related]
9. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946 [TBL] [Abstract][Full Text] [Related]
10. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909 [TBL] [Abstract][Full Text] [Related]
11. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837 [TBL] [Abstract][Full Text] [Related]
12. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up. el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951 [TBL] [Abstract][Full Text] [Related]
13. Application of quantitative analysis to biologic profile evaluation in breast cancer. Querzoli P; Ferretti S; Albonico G; Magri E; Scapoli D; Indelli M; Nenci I Cancer; 1995 Dec; 76(12):2510-7. PubMed ID: 8625078 [TBL] [Abstract][Full Text] [Related]
14. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein. Recăreanu F; Simionescu C; Georgescu CV; Pirici E Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825 [TBL] [Abstract][Full Text] [Related]
15. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens MR J Clin Pathol; 2005 Jun; 58(6):611-6. PubMed ID: 15917412 [TBL] [Abstract][Full Text] [Related]
16. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer. Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer. Cubukcu E; Kanat O; Fatih Olmez O; Kabul S; Canhoroz M; Avci N; Deligonul A; Hartavi M; Cubukcu S; Olmez F; Kurt E; Evrensel T; Gokgoz S; Manavoglu O J BUON; 2013; 18(2):359-65. PubMed ID: 23818346 [TBL] [Abstract][Full Text] [Related]
18. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan. Sharif MA; Mamoon N; Mushtaq S; Khadim MT J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313 [TBL] [Abstract][Full Text] [Related]
19. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen. Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639 [TBL] [Abstract][Full Text] [Related]
20. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania. Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]